首页 > 最新文献

Advanced pharmaceutical bulletin最新文献

英文 中文
Niosome as a Drug Delivery Carrier for Sorafenib: Preparation, Investigation of Physicochemical Properties, and In Vitro Effects on HepG2 Cell Line. 索拉非尼药物递送载体Niosome的制备、理化性质研究及其对HepG2细胞系的体外作用
IF 3.1 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-30 Epub Date: 2024-10-02 DOI: 10.34172/apb.43228
Mohammad Amin Raeisi Estabragh, Behzad Behnam, Masoud Torkzadeh-Mahani, Abbas Pardakhty

Purpose: Sorafenib is known as one of the oral anti-cancer drugs used in liver cancer. However, its lipophilic nature can lead to side effects, variable pharmacokinetics, and poor absorption. The use of novel drug delivery systems, such as niosomes, may help address these issues and improve the effectiveness of sorafenib.

Methods: Different niosomal formulations of sorafenib were prepared. The morphology, size analysis, and physical stability were investigated. The encapsulation efficiency percent of the selected formulations was measured using the dialysis method, and the release of sorafenib was checked for four hours using the Franz diffusion cell. The cytotoxicity and in vitro effect on the HepG2 cell line was investigated using the MTT assay and flow cytometry.

Results: The mean volume diameter of Span 60/Tween 60/cholesterol (45/45/10 mole%) niosomal formulation was 6 µm with minimal size changes and good stability over six months of storage. The encapsulation efficiency percent of this formulation was 66.40±1.11, and 61.43±1.42 percent of the drug was released within 4 hours. In vitro release followed Higuchi kinetics. Cytotoxicity tests showed an IC50 of 7.5 µg/mL for the niosomal formulation, compared to 15.96 µg/mL for the sorafenib solution.

Conclusion: Niosomes containing Span 60/ Tween 60/ cholesterol (45/45/10 mole%) are promising for loading and sustained release of sorafenib. The use of niosome as a carrier can enhance the effectiveness of sorafenib on the HepG2 cell line. This niosomal formulation of sorafenib shows potential for future studies.

目的:众所周知,索拉非尼是用于治疗肝癌的口服抗癌药物之一。然而,索拉非尼的亲脂性可能会导致副作用、药代动力学多变和吸收不良。使用新型给药系统(如niosomes)可能有助于解决这些问题并提高索拉非尼的疗效:方法:制备了不同的索拉非尼niosomal制剂。方法:制备了不同的索拉非尼niosomal制剂,对其形态、粒度分析和物理稳定性进行了研究。采用透析法测量了所选制剂的包封效率百分比,并使用弗朗兹扩散池检测了索拉非尼四小时的释放情况。使用 MTT 法和流式细胞术研究了对 HepG2 细胞株的细胞毒性和体外效应:结果:Span 60/Tween 60/cholesterol (45/45/10 mole%) niosomal 配方的平均体积直径为 6 微米,尺寸变化极小,储存 6 个月后稳定性良好。该制剂的封装效率为 66.40±1.11%,61.43±1.42%的药物在 4 小时内释放。体外释放遵循樋口动力学。细胞毒性测试表明,与索拉非尼溶液的 15.96 微克/毫升相比,niosomal 制剂的 IC50 为 7.5 微克/毫升:含有司盘 60/ 吐温 60/ 胆固醇(45/45/10 摩尔%)的niosomes具有装载和持续释放索拉非尼的前景。使用niosome作为载体可以增强索拉非尼对HepG2细胞系的疗效。这种索拉非尼的niosomal制剂显示了未来研究的潜力。
{"title":"Niosome as a Drug Delivery Carrier for Sorafenib: Preparation, Investigation of Physicochemical Properties, and <i>In Vitro</i> Effects on HepG2 Cell Line.","authors":"Mohammad Amin Raeisi Estabragh, Behzad Behnam, Masoud Torkzadeh-Mahani, Abbas Pardakhty","doi":"10.34172/apb.43228","DOIUrl":"10.34172/apb.43228","url":null,"abstract":"<p><strong>Purpose: </strong>Sorafenib is known as one of the oral anti-cancer drugs used in liver cancer. However, its lipophilic nature can lead to side effects, variable pharmacokinetics, and poor absorption. The use of novel drug delivery systems, such as niosomes, may help address these issues and improve the effectiveness of sorafenib.</p><p><strong>Methods: </strong>Different niosomal formulations of sorafenib were prepared. The morphology, size analysis, and physical stability were investigated. The encapsulation efficiency percent of the selected formulations was measured using the dialysis method, and the release of sorafenib was checked for four hours using the Franz diffusion cell. The cytotoxicity and <i>in vitro</i> effect on the HepG2 cell line was investigated using the MTT assay and flow cytometry.</p><p><strong>Results: </strong>The mean volume diameter of Span 60/Tween 60/cholesterol (45/45/10 mole%) niosomal formulation was 6 µm with minimal size changes and good stability over six months of storage. The encapsulation efficiency percent of this formulation was 66.40±1.11, and 61.43±1.42 percent of the drug was released within 4 hours. <i>In vitro</i> release followed Higuchi kinetics. Cytotoxicity tests showed an IC<sub>50</sub> of 7.5 µg/mL for the niosomal formulation, compared to 15.96 µg/mL for the sorafenib solution.</p><p><strong>Conclusion: </strong>Niosomes containing Span 60/ Tween 60/ cholesterol (45/45/10 mole%) are promising for loading and sustained release of sorafenib. The use of niosome as a carrier can enhance the effectiveness of sorafenib on the HepG2 cell line. This niosomal formulation of sorafenib shows potential for future studies.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"14 4","pages":"836-845"},"PeriodicalIF":3.1,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970492/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Purinergic Receptor (P2X7R): A Promising Anti-Parkinson's Drug Target. 嘌呤能受体(P2X7R):一个有前景的抗帕金森药物靶点。
IF 3.1 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-30 Epub Date: 2024-12-18 DOI: 10.34172/apb.43206
Saivarshini Magham, M Lalith Kumar, Praveen Thaggikuppe Krishnamurthy, Neenu Shaji, Aishwarya Reddy Ramakkamma

Purpose: Parkinson's disease (PD) is the fourth most common neurodegenerative disorder, characterized by degeneration of basal ganglia and a decrease in dopamine levels in the brain. Purinergic 2X7 receptors (P2X7Rs) serve as inflammation gatekeepers. They are found in both central and peripheral nervous systems (CNS & PNS), and are activated in glial cells during inflammation. Purinergic 2X receptors (P2XRs) have been extensively studied in recent decades, particularly P2X7R, because of their important role in neuroinflammation caused by selective overexpression in glial cells. As P2X7R and its selective antagonists may provide neuroprotection by preventing the release of inflammatory mediators such as IL-1, they have become a research focus in PD. The review covers structure, signalling, molecular mechanisms, neuroprotective role, and current developments of P2X7R antagonists in PD.

Methods: A systematic analysis and review of the potential prospects of P2X7R antagonists in the treatment of PD were conducted by analyzing existing research data and reports published between 1996 and present.

Results: There is a substantial body of evidence linking P2X7R to pathology of PD. As a result, P2X7R antagonists may have therapeutic potential in treatment of PD.

Conclusion: P2X7R has been demonstrated as an efficacious target in PD. Recent advances in rational drug design have paved the way for development of therapeutically valuable P2X7R antagonists such as adamantyl cyanoguanides, small molecular weight compounds, and PET ligands for the treatment of PD. However, the exact molecular mechanism and therapeutic potential of P2X7R antagonists in treatment of PD are yet to be fully explored.

目的:帕金森病(PD)是第四大最常见的神经退行性疾病,其特征是基底神经节变性和大脑多巴胺水平降低。嘌呤能2X7受体(P2X7Rs)是炎症的守门人。它们存在于中枢和周围神经系统(CNS & PNS)中,并在炎症期间在胶质细胞中被激活。嘌呤能2X受体(P2XRs)在近几十年来被广泛研究,特别是P2X7R,因为它们在神经胶质细胞选择性过表达引起的神经炎症中起重要作用。由于P2X7R及其选择性拮抗剂可能通过阻止IL-1等炎症介质的释放而起到神经保护作用,因此成为帕金森病的研究热点。本文综述了P2X7R拮抗剂在帕金森病中的结构、信号传导、分子机制、神经保护作用和研究进展。方法:通过分析1996年至今已有的研究资料和发表的相关报道,对P2X7R拮抗剂治疗PD的潜在前景进行系统分析和综述。结果:有大量证据表明P2X7R与PD的病理有关。因此,P2X7R拮抗剂可能在治疗PD方面具有治疗潜力。结论:P2X7R是治疗帕金森病的有效靶点。合理药物设计的最新进展为开发具有治疗价值的P2X7R拮抗剂铺平了道路,如金刚烷基氰胍、小分子量化合物和PET配体,用于治疗PD。然而,P2X7R拮抗剂治疗PD的确切分子机制和治疗潜力尚未得到充分探索。
{"title":"Purinergic Receptor (P2X7R): A Promising Anti-Parkinson's Drug Target.","authors":"Saivarshini Magham, M Lalith Kumar, Praveen Thaggikuppe Krishnamurthy, Neenu Shaji, Aishwarya Reddy Ramakkamma","doi":"10.34172/apb.43206","DOIUrl":"10.34172/apb.43206","url":null,"abstract":"<p><strong>Purpose: </strong>Parkinson's disease (PD) is the fourth most common neurodegenerative disorder, characterized by degeneration of basal ganglia and a decrease in dopamine levels in the brain. Purinergic 2X7 receptors (P2X7Rs) serve as inflammation gatekeepers. They are found in both central and peripheral nervous systems (CNS & PNS), and are activated in glial cells during inflammation. Purinergic 2X receptors (P2XRs) have been extensively studied in recent decades, particularly P2X7R, because of their important role in neuroinflammation caused by selective overexpression in glial cells. As P2X7R and its selective antagonists may provide neuroprotection by preventing the release of inflammatory mediators such as IL-1, they have become a research focus in PD. The review covers structure, signalling, molecular mechanisms, neuroprotective role, and current developments of P2X7R antagonists in PD.</p><p><strong>Methods: </strong>A systematic analysis and review of the potential prospects of P2X7R antagonists in the treatment of PD were conducted by analyzing existing research data and reports published between 1996 and present.</p><p><strong>Results: </strong>There is a substantial body of evidence linking P2X7R to pathology of PD. As a result, P2X7R antagonists may have therapeutic potential in treatment of PD.</p><p><strong>Conclusion: </strong>P2X7R has been demonstrated as an efficacious target in PD. Recent advances in rational drug design have paved the way for development of therapeutically valuable P2X7R antagonists such as adamantyl cyanoguanides, small molecular weight compounds, and PET ligands for the treatment of PD. However, the exact molecular mechanism and therapeutic potential of P2X7R antagonists in treatment of PD are yet to be fully explored.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"14 4","pages":"807-818"},"PeriodicalIF":3.1,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolomic Approach in Anticancer Biomarker Discovery from Foliose Lichens. 利用代谢组学方法发现叶酸地衣抗癌生物标志物。
IF 3.1 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-30 Epub Date: 2024-12-13 DOI: 10.34172/apb.43220
Chintya Permata Zahky Sukrisno Putri, Dinar Mutia Rani, Ludmilla Fitri Untari, Banun Kusumawardani, Anang Kurnia, Paul A Keller, Ari Satia Nugraha

Purpose: Lichens are well-known as a source of pharmacologically active compounds. This includes anticancer compounds which have biomass constraints including using traditional techniques of lichen bioprospecting. This current study reports the use of cutting-edge metabolomics and a computational approach to discover anticancer biomarkers from Indonesian lichens.

Methods: Seven lichen crude extracts were evaluated against cervical cell lines HeLa using a MTT assay and secondary metabolites were profiled and recorded via a gas chromatography-mass spectrometry (GC-MS) protocol. A multivariate analysis orthogonal partial least-squares-discriminant analysis (OPLS-DA) was employed to determine anticancer biomarker of the lichens. A structure-based computational study against the HeLa cancer cell related protein targets (BCL-2 (4MAN), AKT-1 (4GV1), MCL-1 (5FDO), and BRAF (5VAM)) was used to determine the most potent biomarker.

Results: The MTT assessment indicated the seven lichens possessed strong, medium and weak cytotoxicity. Multivariate analysis showed an OPLS-DA score plot with distinct separation among the strong, medium and weak cytotoxic groups. The biplot OPLS-DA and GC-MS analysis proposed 13 compounds of Parmelia caroliniana and 12 compounds of Physcia cf. millegrana as anticancer biomarker candidates. Docking experiments revealed 6-amino-3,4,7-triphenylpyrido[2',3':4,5]thieno[2,3-c]pyridazine 4 from P. caroliniana to possess the highest binding affinity against BCL-2 (4MAN), AKT-1 (4GV1), MCL-1 (5FDO), and BRAF (5VAM) proteins with affinity energy values of -10.0, -11.6, -10.4, -12.6, respectively.

Conclusion: The study successfully revealed compound 4 as the anticancer biomarker against HeLa cell cancer of P. caroliniana in which can be further explored through in vitro and in vivo studies. Further, the metabolomic protocol established can be adapted as a tool for biomarker discoveries from other medicinal plants.

目的:地衣是众所周知的药理活性化合物的来源。这包括具有生物量限制的抗癌化合物,包括使用传统的地衣生物勘探技术。本研究报告了使用尖端代谢组学和计算方法从印度尼西亚地衣中发现抗癌生物标志物。方法:采用MTT法测定7种地衣粗提物对宫颈细胞株HeLa的抑制作用,并采用气相色谱-质谱联用(GC-MS)法分析地衣粗提物的次生代谢产物。采用多变量正交偏最小二乘判别分析(OPLS-DA)测定地衣的抗癌生物标志物。一项针对HeLa癌细胞相关蛋白靶点(BCL-2 (4MAN), AKT-1 (4GV1), MCL-1 (5FDO)和BRAF (5VAM))的基于结构的计算研究用于确定最有效的生物标志物。结果:7种地衣分别具有强、中、弱细胞毒性。多因素分析显示,OPLS-DA评分图在强、中、弱细胞毒组之间有明显的分离。双图OPLS-DA和GC-MS分析提出了13种Parmelia caroliniana化合物和12种physia cff . millegrana化合物作为抗癌生物标志物候选物。对接实验发现,来自P. caroliniana的6-氨基-3,4,7-三苯基吡啶do[2',3':4,5]thieno[2,3-c]pyridazine 4对BCL-2 (4MAN)、AKT-1 (4GV1)、MCL-1 (5FDO)和BRAF (5VAM)蛋白具有最高的结合亲和力,亲和能值分别为-10.0、-11.6、-10.4、-12.6。结论:本研究成功揭示了化合物4可作为P. caroliniana HeLa细胞癌的抗癌生物标志物,其在体外和体内研究中有待进一步探索。此外,建立的代谢组学方案可以作为从其他药用植物中发现生物标志物的工具。
{"title":"Metabolomic Approach in Anticancer Biomarker Discovery from Foliose Lichens.","authors":"Chintya Permata Zahky Sukrisno Putri, Dinar Mutia Rani, Ludmilla Fitri Untari, Banun Kusumawardani, Anang Kurnia, Paul A Keller, Ari Satia Nugraha","doi":"10.34172/apb.43220","DOIUrl":"10.34172/apb.43220","url":null,"abstract":"<p><strong>Purpose: </strong>Lichens are well-known as a source of pharmacologically active compounds. This includes anticancer compounds which have biomass constraints including using traditional techniques of lichen bioprospecting. This current study reports the use of cutting-edge metabolomics and a computational approach to discover anticancer biomarkers from Indonesian lichens.</p><p><strong>Methods: </strong>Seven lichen crude extracts were evaluated against cervical cell lines HeLa using a MTT assay and secondary metabolites were profiled and recorded via a gas chromatography-mass spectrometry (GC-MS) protocol. A multivariate analysis orthogonal partial least-squares-discriminant analysis (OPLS-DA) was employed to determine anticancer biomarker of the lichens. A structure-based computational study against the HeLa cancer cell related protein targets (BCL-2 (4MAN), AKT-1 (4GV1), MCL-1 (5FDO), and BRAF (5VAM)) was used to determine the most potent biomarker.</p><p><strong>Results: </strong>The MTT assessment indicated the seven lichens possessed strong, medium and weak cytotoxicity. Multivariate analysis showed an OPLS-DA score plot with distinct separation among the strong, medium and weak cytotoxic groups. The biplot OPLS-DA and GC-MS analysis proposed 13 compounds of <i>Parmelia caroliniana</i> and 12 compounds of <i>Physcia cf. millegrana</i> as anticancer biomarker candidates. Docking experiments revealed 6-amino-3,4,7-triphenylpyrido[2',3':4,5]thieno[2,3-<i>c</i>]pyridazine <b>4</b> from <i>P. caroliniana</i> to possess the highest binding affinity against BCL-2 (4MAN), AKT-1 (4GV1), MCL-1 (5FDO), and BRAF (5VAM) proteins with affinity energy values of -10.0, -11.6, -10.4, -12.6, respectively.</p><p><strong>Conclusion: </strong>The study successfully revealed compound <b>4</b> as the anticancer biomarker against HeLa cell cancer of <i>P. caroliniana</i> in which can be further explored through <i>in vitro</i> and <i>in vivo</i> studies. Further, the metabolomic protocol established can be adapted as a tool for biomarker discoveries from other medicinal plants.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"14 4","pages":"938-943"},"PeriodicalIF":3.1,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rethinking the Complexation of Phytochemicals in Natural β-Cyclodextrins. 再思考天然β-环糊精中植物化学物质的络合作用。
IF 3.1 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-30 Epub Date: 2024-10-30 DOI: 10.34172/apb.43888
Ian Jhemes Oliveira Sousa, Rita de Cássia Meneses Oliveira
{"title":"Rethinking the Complexation of Phytochemicals in Natural β-Cyclodextrins.","authors":"Ian Jhemes Oliveira Sousa, Rita de Cássia Meneses Oliveira","doi":"10.34172/apb.43888","DOIUrl":"10.34172/apb.43888","url":null,"abstract":"","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"14 4","pages":"718-719"},"PeriodicalIF":3.1,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970486/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted Therapy Evolution from Defining a Sub-population to Crossing Multi-indications. 靶向治疗从限定亚群到跨越多适应症的演变。
IF 3.1 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-30 Epub Date: 2024-09-15 DOI: 10.34172/apb.43306
Daohong Chen

Purpose: It tends not only to shed lights on an emerging classification framework of disease according to the shared molecular pathogenesis across various organs/tissues, but also to inspire more efficient paradigms of pharmaceutic innovation in a broader medical perspective.

Methods: Literature review and re-thinking.

Results: This article has sorted out an updated profile of the outstanding targeted medications with an extending list of clinical indications in oncology and beyond.

Conclusion: Pharmaceutic development can be processed in a less risky and more affordable manner through drug repurpose or tissue agnostic approval.

目的:它不仅揭示了一种新兴的疾病分类框架,根据不同器官/组织的共同分子发病机制,而且在更广泛的医学视角下激发更有效的药物创新范式。方法:文献复习和再思考。结果:本文整理了肿瘤及其他领域突出的靶向药物的最新概况,并扩展了临床适应症。结论:通过药物再用途或组织不可知性审批,可以降低药物开发的风险和成本。
{"title":"Targeted Therapy Evolution from Defining a Sub-population to Crossing Multi-indications.","authors":"Daohong Chen","doi":"10.34172/apb.43306","DOIUrl":"10.34172/apb.43306","url":null,"abstract":"<p><strong>Purpose: </strong>It tends not only to shed lights on an emerging classification framework of disease according to the shared molecular pathogenesis across various organs/tissues, but also to inspire more efficient paradigms of pharmaceutic innovation in a broader medical perspective.</p><p><strong>Methods: </strong>Literature review and re-thinking.</p><p><strong>Results: </strong>This article has sorted out an updated profile of the outstanding targeted medications with an extending list of clinical indications in oncology and beyond.</p><p><strong>Conclusion: </strong>Pharmaceutic development can be processed in a less risky and more affordable manner through drug repurpose or tissue agnostic approval.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"14 4","pages":"737-744"},"PeriodicalIF":3.1,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970494/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unmasking Greenwashing: Mapping Hijacked Medicine Journals to the Sustainable Development Goals. 揭露洗绿:将被劫持的医学期刊映射到可持续发展目标。
IF 3.1 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-30 Epub Date: 2024-09-24 DOI: 10.34172/apb.43763
Mihály Hegedűs, Mehdi Dadkhah, Lóránt Dénes Dávid

Purpose: Hijacked journals are journals managed by cybercriminals that mimic the original journal and publish manuscripts without peer review, charging a fee to the author. Although there is literature on hijacked journals, there is a gap in the content of published papers in the hijacked journals. This study aims to analyze the content of published papers in hijacked journals to assess their alignment with various Sustainable Development Goals (SDGs).

Methods: About 21 medicine journals have been investigated and about 3300 published manuscripts in them analyzed in terms of SDGs using the text-based analyzing method.

Results: The findings indicated that published manuscripts fit in the categories of SDG 01, SDG 03, SDG 11, and SDG 16 where SDG-03 is most dominant.

Conclusion: The awareness about the problem of hijacked journals is critical, especially for developing countries, to eliminate the negative effects of these journals. It is the first research that discusses the negative effect of hijacked journals by considering SDGs and sheds light on the phenomenon.

目的:被劫持的期刊是由网络罪犯管理的期刊,他们模仿原始期刊,在没有同行评审的情况下发表手稿,向作者收取费用。虽然有关于被劫持期刊的文献,但在被劫持期刊上发表的论文内容上存在空白。本研究旨在分析被劫持期刊上发表的论文内容,以评估其与各种可持续发展目标(sdg)的一致性。方法:采用基于文本的分析方法,对21种医学期刊进行调查,并对其中发表的约3300篇论文进行sdg分析。结果:研究结果表明,已发表稿件符合SDG 01、SDG 03、SDG 11和SDG 16类别,其中SDG-03占主导地位。结论:对劫持期刊问题的认识对于消除这些期刊的负面影响至关重要,特别是对发展中国家而言。这是第一次考虑到可持续发展目标,讨论被劫持期刊的负面影响,并揭示了这一现象。
{"title":"Unmasking Greenwashing: Mapping Hijacked Medicine Journals to the Sustainable Development Goals.","authors":"Mihály Hegedűs, Mehdi Dadkhah, Lóránt Dénes Dávid","doi":"10.34172/apb.43763","DOIUrl":"10.34172/apb.43763","url":null,"abstract":"<p><strong>Purpose: </strong>Hijacked journals are journals managed by cybercriminals that mimic the original journal and publish manuscripts without peer review, charging a fee to the author. Although there is literature on hijacked journals, there is a gap in the content of published papers in the hijacked journals. This study aims to analyze the content of published papers in hijacked journals to assess their alignment with various Sustainable Development Goals (SDGs).</p><p><strong>Methods: </strong>About 21 medicine journals have been investigated and about 3300 published manuscripts in them analyzed in terms of SDGs using the text-based analyzing method.</p><p><strong>Results: </strong>The findings indicated that published manuscripts fit in the categories of SDG 01, SDG 03, SDG 11, and SDG 16 where SDG-03 is most dominant.</p><p><strong>Conclusion: </strong>The awareness about the problem of hijacked journals is critical, especially for developing countries, to eliminate the negative effects of these journals. It is the first research that discusses the negative effect of hijacked journals by considering SDGs and sheds light on the phenomenon.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"14 4","pages":"729-736"},"PeriodicalIF":3.1,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Agaricus bisporus Mannose-Binding Protein Stimulates the Innate Immune Cells. 双孢蘑菇甘露糖结合蛋白刺激先天免疫细胞。
IF 3.1 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-30 Epub Date: 2024-12-13 DOI: 10.34172/apb.43767
Wangsa Tirta Ismaya, Agung Heru Karsono, Olivia Mayasari Tandrasasmita, Raymond Rubianto Tjandrawinata, Heni Rachmawati

Purpose: A lectin-like protein from the mushroom Agaricus bisporus has been shown to slightly increase the proliferation of RAW 264.7 cells. Following its identification as a mannose-binding lectin, henceforth called A. bisporus mannose-binding protein (Abmb), the protein is hypothesized to stimulate the innate immune cells response. The present work was aimed to substantiate that hypothesis. Furthermore, this study complements Abmb exploration as a potential agent for anti-breast cancer, which its treatment is hampered with compromised immunity of patient receiving chemotherapy.

Methods: Abmb's effect on the phagocytic activity of the macrophage was measured with FACS. Nitric oxide (NO) production was checked using Griess test while expression of the cytokines in the RAW 264.7 cells was analysed at gene and protein level using polymerase chain reaction (PCR) and FACS, respectively. Abmb's effect on the expression of surface markers of the human immune cells in the peripheral blood mononuclear cells (PBMCs) was checked with specific antibodies for targeted cluster differentiation (CD) and analysed using FACS.

Results: Abmb increased the phagocytic activity of the macrophage and NO production. Abmb increased the expression of cytokines i.e. tumour necrosis factor (TNF)-α, interleukin (IL)-6, and IL-10. With the PBMCs, Abmb activated dendritic and natural killer (NK) cells, but not the B- or T-cells.

Conclusion: Abmb increased the activity of the macrophage cells and activated the immune cells that are related to the innate immune system, particularly the cellular immunity.

目的:研究表明,来自双孢蘑菇的一种凝集素样蛋白可轻微增加 RAW 264.7 细胞的增殖。在被鉴定为甘露糖结合凝集素(下文称作双孢蘑菇甘露糖结合蛋白(Abmb))后,该蛋白被假定能刺激先天性免疫细胞的反应。本研究旨在证实这一假设。此外,这项研究还补充了 Abmb 作为抗乳腺癌潜在药物的探索,因为接受化疗的病人免疫力下降,阻碍了乳腺癌的治疗:方法:用 FACS 测量 Abmb 对巨噬细胞吞噬活性的影响。方法:利用 FACS 测定 Abmb 对巨噬细胞吞噬活性的影响;利用 Griess 试验检测一氧化氮(NO)的产生;利用聚合酶链反应(PCR)和 FACS 分别从基因和蛋白质水平分析 RAW 264.7 细胞中细胞因子的表达。用特异性抗体检测 Abmb 对外周血单核细胞(PBMCs)中人类免疫细胞表面标志物表达的影响,并使用 FACS 进行分析:结果:Abmb 提高了巨噬细胞的吞噬活性和 NO 的产生。Abmb 增加了肿瘤坏死因子(TNF)-α、白细胞介素(IL)-6 和 IL-10 等细胞因子的表达。Abmb 可激活树突状细胞和自然杀伤(NK)细胞,但不能激活 B 细胞或 T 细胞:结论:Abmb提高了巨噬细胞的活性,激活了与先天性免疫系统有关的免疫细胞,尤其是细胞免疫。
{"title":"<i>Agaricus bisporus</i> Mannose-Binding Protein Stimulates the Innate Immune Cells.","authors":"Wangsa Tirta Ismaya, Agung Heru Karsono, Olivia Mayasari Tandrasasmita, Raymond Rubianto Tjandrawinata, Heni Rachmawati","doi":"10.34172/apb.43767","DOIUrl":"10.34172/apb.43767","url":null,"abstract":"<p><strong>Purpose: </strong>A lectin-like protein from the mushroom <i>Agaricus bisporus</i> has been shown to slightly increase the proliferation of RAW 264.7 cells. Following its identification as a mannose-binding lectin, henceforth called <i>A. bisporus</i> mannose-binding protein (Abmb), the protein is hypothesized to stimulate the innate immune cells response. The present work was aimed to substantiate that hypothesis. Furthermore, this study complements Abmb exploration as a potential agent for anti-breast cancer, which its treatment is hampered with compromised immunity of patient receiving chemotherapy.</p><p><strong>Methods: </strong>Abmb's effect on the phagocytic activity of the macrophage was measured with FACS. Nitric oxide (NO) production was checked using Griess test while expression of the cytokines in the RAW 264.7 cells was analysed at gene and protein level using polymerase chain reaction (PCR) and FACS, respectively. Abmb's effect on the expression of surface markers of the human immune cells in the peripheral blood mononuclear cells (PBMCs) was checked with specific antibodies for targeted cluster differentiation (CD) and analysed using FACS.</p><p><strong>Results: </strong>Abmb increased the phagocytic activity of the macrophage and NO production. Abmb increased the expression of cytokines <i>i.e.</i> tumour necrosis factor (TNF)-α, interleukin (IL)-6, and IL-10. With the PBMCs, Abmb activated dendritic and natural killer (NK) cells, but not the B- or T-cells.</p><p><strong>Conclusion: </strong>Abmb increased the activity of the macrophage cells and activated the immune cells that are related to the innate immune system, particularly the cellular immunity.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"14 4","pages":"944-950"},"PeriodicalIF":3.1,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Applications of Hydroxyapatite-Based Polymeric Scaffolds in Bone Tissue Engineering: An Update. 羟基磷灰石基聚合物支架在骨组织工程中的应用进展
IF 3.1 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-30 Epub Date: 2024-10-16 DOI: 10.34172/apb.43818
Nazanin Amiryaghoubi, Rana Jahanban Esfahlan

Bone organ is comprised of an organic and inorganic environment, in which the collagen element and the mineral part are structured into spongy constructions. Hydroxyapatite (HAp) is the chief inorganic constituent of human bone. HAp is extensively utilized in bone tissue regeneration for its biocompatibility and a rising number of investigators are discovering ways to recover the physical belongings and biological roles of HAp. However, this biomimetic material indicates poor mechanical strength, for example, low tensile and compressive strength, which offer it inappropriate for bone tissue engineering. For this point, HAp is frequently utilized in a mixture with diverse polymers to increase their mechanical strengths and the general function of the implantable biomaterials advanced for orthopedic usage. In this review, we attempt to contribute a brief and inclusive outline of HAp-based natural and synthetic polymer materials to strengthen structures and their applications in bone tissue regeneration.

骨骼器官由有机和无机环境组成,其中胶原元素和矿物质部分形成海绵状结构。羟基磷灰石(HAp)是人体骨骼的主要无机成分。HAp 因其生物相容性而被广泛用于骨组织再生,越来越多的研究人员正在探索如何恢复 HAp 的物理属性和生物作用。然而,这种仿生物材料的机械强度较差,例如拉伸强度和压缩强度较低,因此不适合用于骨组织工程。因此,HAp 经常与不同的聚合物混合使用,以提高其机械强度和骨科用植入式生物材料的一般功能。在这篇综述中,我们试图对基于 HAp 的天然和合成聚合物材料在骨组织再生中的强化结构及其应用进行简要而全面的概述。
{"title":"Applications of Hydroxyapatite-Based Polymeric Scaffolds in Bone Tissue Engineering: An Update.","authors":"Nazanin Amiryaghoubi, Rana Jahanban Esfahlan","doi":"10.34172/apb.43818","DOIUrl":"10.34172/apb.43818","url":null,"abstract":"<p><p>Bone organ is comprised of an organic and inorganic environment, in which the collagen element and the mineral part are structured into spongy constructions. Hydroxyapatite (HAp) is the chief inorganic constituent of human bone. HAp is extensively utilized in bone tissue regeneration for its biocompatibility and a rising number of investigators are discovering ways to recover the physical belongings and biological roles of HAp. However, this biomimetic material indicates poor mechanical strength, for example, low tensile and compressive strength, which offer it inappropriate for bone tissue engineering. For this point, HAp is frequently utilized in a mixture with diverse polymers to increase their mechanical strengths and the general function of the implantable biomaterials advanced for orthopedic usage. In this review, we attempt to contribute a brief and inclusive outline of HAp-based natural and synthetic polymer materials to strengthen structures and their applications in bone tissue regeneration.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"14 4","pages":"794-806"},"PeriodicalIF":3.1,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cell Therapy Using Anti-NKG2A Pretreated Natural Killer Cells in Patients with Hepatocellular Carcinoma. 抗nkg2a预处理的自然杀伤细胞在肝癌患者中的细胞治疗
IF 3.1 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-30 Epub Date: 2024-12-05 DOI: 10.34172/apb.43869
Shirin Tavakoli, Maryam Samareh-Salavati, Shahrokh Abdolahi, Javad Verdi, Iman Seyhoun, Nasim Vousooghi, Mohammad Vaezi, Afshin Ghaderi, Ardeshir Ghavamzadeh, Maryam Barkhordar, Mohammad Ahmadvand

Purpose: The activities and functions of natural killer (NK) cells are regulated by a limited repertoire of activating and inhibitory receptors. Thus, we provided a study of inhibition of the NKG2A using monoclonal antibodies (mAbs), and as a primary endpoint, we evaluated whether it can be translated to enhance adoptive NK cell immunotherapy, as the secondary endpoint, we investigated safety and feasibility.

Methods: In this study, we investigated the safety of anti-NKG2A-pretreated NK cells in improving ADCC function to manage hepatocellular carcinoma (HCC). After a conditioning regimen, we initiated a pilot study of expanded donor haploidentical NK cell infusion. Patients received a fludarabine/cyclophosphamide conditioning followed by adoptive immunotherapy with IL2-activated haploidentical NK cells. Anti-NKG2A pretreated NK cells were infused on days 0,+5, and+10 post-conditioning regimens at a dose of 7×108 cells (n=3). The median follow-up was 4 months for all patients.

Results: Although all patients were alive at the last follow-up, two of them showed progressive disease and an increase in tumor size. In addition, all patients showed a relative decrease in alpha-fetoprotein (AFP) expression levels after one month.

Conclusion: This study demonstrated the safety and feasibility of infusing high doses of ex vivo expanded NK cells after conditioning with transient side effects.

目的:NK细胞的活性和功能是由有限的激活和抑制受体调控的。因此,我们利用单克隆抗体(mab)对NKG2A进行了抑制研究,作为主要终点,我们评估了它是否可以被翻译为增强过继NK细胞免疫治疗,作为次要终点,我们研究了安全性和可行性。方法:在本研究中,我们研究了抗nkg2a预处理的NK细胞在改善ADCC功能治疗肝细胞癌(HCC)中的安全性。经过调理方案后,我们开始了一项扩大供体单倍体NK细胞输注的试点研究。患者接受氟达拉滨/环磷酰胺调理,随后采用il - 2激活的单倍体NK细胞进行过继免疫治疗。抗nkg2a预处理的NK细胞分别于第0、+5和+10天以7×108细胞剂量输注(n=3)。所有患者的中位随访时间为4个月。结果:虽然所有患者在最后一次随访时都存活,但其中2例出现疾病进展和肿瘤大小增加。此外,所有患者在1个月后甲胎蛋白(AFP)表达水平均出现相对下降。结论:本研究证明了大剂量体外扩增NK细胞经调理后输注的安全性和可行性,并伴有短暂的副作用。
{"title":"Cell Therapy Using Anti-NKG2A Pretreated Natural Killer Cells in Patients with Hepatocellular Carcinoma.","authors":"Shirin Tavakoli, Maryam Samareh-Salavati, Shahrokh Abdolahi, Javad Verdi, Iman Seyhoun, Nasim Vousooghi, Mohammad Vaezi, Afshin Ghaderi, Ardeshir Ghavamzadeh, Maryam Barkhordar, Mohammad Ahmadvand","doi":"10.34172/apb.43869","DOIUrl":"10.34172/apb.43869","url":null,"abstract":"<p><strong>Purpose: </strong>The activities and functions of natural killer (NK) cells are regulated by a limited repertoire of activating and inhibitory receptors. Thus, we provided a study of inhibition of the NKG2A using monoclonal antibodies (mAbs), and as a primary endpoint, we evaluated whether it can be translated to enhance adoptive NK cell immunotherapy, as the secondary endpoint, we investigated safety and feasibility.</p><p><strong>Methods: </strong>In this study, we investigated the safety of anti-NKG2A-pretreated NK cells in improving ADCC function to manage hepatocellular carcinoma (HCC). After a conditioning regimen, we initiated a pilot study of expanded donor haploidentical NK cell infusion. Patients received a fludarabine/cyclophosphamide conditioning followed by adoptive immunotherapy with IL2-activated haploidentical NK cells. Anti-NKG2A pretreated NK cells were infused on days 0,+5, and+10 post-conditioning regimens at a dose of 7×10<sup>8</sup> cells (n=3). The median follow-up was 4 months for all patients.</p><p><strong>Results: </strong>Although all patients were alive at the last follow-up, two of them showed progressive disease and an increase in tumor size. In addition, all patients showed a relative decrease in alpha-fetoprotein (AFP) expression levels after one month.</p><p><strong>Conclusion: </strong>This study demonstrated the safety and feasibility of infusing high doses of ex vivo expanded NK cells after conditioning with transient side effects.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"14 4","pages":"918-926"},"PeriodicalIF":3.1,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Optimized Method for Single Cell Cloning of Human CAR-T Cells Based on FBS-Coated Plates. 基于fbs包被板的人CAR-T细胞单细胞克隆优化方法
IF 4.1 Q2 PHARMACOLOGY & PHARMACY Pub Date : 2024-12-26 eCollection Date: 2025-04-01 DOI: 10.34172/apb.43798
Mahdie Jafari, Shahriyar Abdoli, Masoud Moghaddam Pour, Mohammad Ali Shokrgozar, Zahra Sharifzadeh

Purpose: T cell-based immunotherapy, especially chimeric antigen receptor (CAR)-T cells, has emerged as an appropriate approach for treating hematologic malignancies and is currently under investigation in clinical trials for solid tumors. Despite significant improvements in CAR-T cell production processes, the isolation and expansion of CAR-engineered T cells continue to pose significant challenges. The aim of this research is to provide a simple and cost-effective method for the isolation and expansion of human CAR-T cells. This novel concept applies coated fetal bovine serum (FBS) culture plates and focuses on enhancing viability and functionality to improve the adherence of suspended T cells.

Methods: This study evaluated a two-dimensional (2D) culture technique for isolating the CAR-T cells that target prostate-specific membrane antigen (PSMA) utilizing matrices pre-coated with 0.2% glutaraldehyde and FBS. Jurkat cells were transduced with a lentiviral vector encoding the anti-PSMA CAR construct. FBS-coated and commercialized Matrigel-coated matrices were used for single-cell isolation and clonal expansion. Functional tests were conducted to assess the activation and proliferation of CAR-T cells and the IFN-γ release assay subsequent to cloning and expansion.

Results: Transfection efficiency markedly improved, with 88.4% of Lenti-X 293T cells demonstrating green fluorescent protein (GFP) expression. Among the Jurkat cells, 57.1% showed GFP expression post-transduction, of which 34.1% showed surface expression of anti-PSMA CAR. Clonal expansion on the FBS-coated matrix proved effective, yielding 92.1% GFP-positive isolated cells. Functional assays demonstrated that CAR-T cells co-cultured with LNCaP cells exhibited significantly enhanced proliferation, activation (as indicated by CD69 and CD25 expression), and cytokine release assay (IFN-γ) compared with those co-cultured with DU 145 and mock cells.

Conclusion: This new approach is efficient, economical, and scalable for isolating specific homogenous T cells and promoting their clonal proliferation and expansion. Furthermore, this method improves T cell adherence, proliferation, and functional effectiveness, offering a potential foundation for advancing CAR-T cell therapies aimed at solid tumors. Future research should concentrate on optimizing culture conditions and testing this method in preclinical animal models to ensure its clinical applicability and efficacy.

目的:基于T细胞的免疫疗法,特别是嵌合抗原受体(CAR)-T细胞,已经成为治疗血液系统恶性肿瘤的一种合适的方法,目前正在实体瘤的临床试验中进行研究。尽管CAR-T细胞的生产工艺有了重大改进,但CAR-T细胞的分离和扩增仍然面临重大挑战。本研究的目的是为人类CAR-T细胞的分离和扩增提供一种简单而经济的方法。这个新概念应用于包被胎牛血清(FBS)培养板,并着重于提高生存能力和功能,以改善悬浮T细胞的粘附性。方法:本研究评估了一种二维(2D)培养技术,用于分离靶向前列腺特异性膜抗原(PSMA)的CAR-T细胞,该技术利用预先包被0.2%戊二醛和FBS的基质。用慢病毒载体编码抗psma CAR构建体转染Jurkat细胞。采用fbs包被和商业化的matrigel包被基质进行单细胞分离和克隆扩增。进行功能测试以评估CAR-T细胞的激活和增殖以及克隆和扩增后的IFN-γ释放试验。结果:转染效率显著提高,88.4%的lti - x 293T细胞表达绿色荧光蛋白(GFP)。57.1%的Jurkat细胞转导后表达GFP,其中34.1%的Jurkat细胞表面表达抗psma CAR。在fbs包被的基质上克隆扩增证明是有效的,获得92.1%的gfp阳性分离细胞。功能分析表明,与LNCaP细胞共培养的CAR-T细胞相比,与DU 145和模拟细胞共培养的CAR-T细胞的增殖、活化(CD69和CD25表达)和细胞因子释放(IFN-γ)均显著增强。结论:该方法可高效、经济、可扩展地分离特异性同质T细胞并促进其克隆增殖和扩增。此外,该方法提高了T细胞的粘附、增殖和功能有效性,为推进针对实体肿瘤的CAR-T细胞治疗提供了潜在的基础。未来的研究应集中在优化培养条件和临床前动物模型上,以确保该方法的临床适用性和有效性。
{"title":"An Optimized Method for Single Cell Cloning of Human CAR-T Cells Based on FBS-Coated Plates.","authors":"Mahdie Jafari, Shahriyar Abdoli, Masoud Moghaddam Pour, Mohammad Ali Shokrgozar, Zahra Sharifzadeh","doi":"10.34172/apb.43798","DOIUrl":"10.34172/apb.43798","url":null,"abstract":"<p><strong>Purpose: </strong>T cell-based immunotherapy, especially chimeric antigen receptor (CAR)-T cells, has emerged as an appropriate approach for treating hematologic malignancies and is currently under investigation in clinical trials for solid tumors. Despite significant improvements in CAR-T cell production processes, the isolation and expansion of CAR-engineered T cells continue to pose significant challenges. The aim of this research is to provide a simple and cost-effective method for the isolation and expansion of human CAR-T cells. This novel concept applies coated fetal bovine serum (FBS) culture plates and focuses on enhancing viability and functionality to improve the adherence of suspended T cells.</p><p><strong>Methods: </strong>This study evaluated a two-dimensional (2D) culture technique for isolating the CAR-T cells that target prostate-specific membrane antigen (PSMA) utilizing matrices pre-coated with 0.2% glutaraldehyde and FBS. Jurkat cells were transduced with a lentiviral vector encoding the anti-PSMA CAR construct. FBS-coated and commercialized Matrigel-coated matrices were used for single-cell isolation and clonal expansion. Functional tests were conducted to assess the activation and proliferation of CAR-T cells and the IFN-γ release assay subsequent to cloning and expansion.</p><p><strong>Results: </strong>Transfection efficiency markedly improved, with 88.4% of Lenti-X 293T cells demonstrating green fluorescent protein (GFP) expression. Among the Jurkat cells, 57.1% showed GFP expression post-transduction, of which 34.1% showed surface expression of anti-PSMA CAR. Clonal expansion on the FBS-coated matrix proved effective, yielding 92.1% GFP-positive isolated cells. Functional assays demonstrated that CAR-T cells co-cultured with LNCaP cells exhibited significantly enhanced proliferation, activation (as indicated by CD69 and CD25 expression), and cytokine release assay (IFN-γ) compared with those co-cultured with DU 145 and mock cells.</p><p><strong>Conclusion: </strong>This new approach is efficient, economical, and scalable for isolating specific homogenous T cells and promoting their clonal proliferation and expansion. Furthermore, this method improves T cell adherence, proliferation, and functional effectiveness, offering a potential foundation for advancing CAR-T cell therapies aimed at solid tumors. Future research should concentrate on optimizing culture conditions and testing this method in preclinical animal models to ensure its clinical applicability and efficacy.</p>","PeriodicalId":7256,"journal":{"name":"Advanced pharmaceutical bulletin","volume":"15 1","pages":"133-142"},"PeriodicalIF":4.1,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235364/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Advanced pharmaceutical bulletin
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1